Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response

OncoImmunology

Volumn 1, Issue 1, 2012, Pages 9-17

  Breban, Romulus ^a   Bisiaux, Aurelie ^b,c   Biot, Claire ^b,c,d   Rentsch, Cyrill A ^b,c,e   Bousso, Philippe ^a,f   Albert, Matthew L ^b,c  

^a INSTITUT PASTEUR   (France)

^b Unité Immunobiologie des Cellules Dendritiques   (France)

^c INSERM   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e UNIVERSITY OF BASEL   (Switzerland)

^f INSTITUT PASTEUR   (France)

Author keywords

Apoptosis; BCG immunotherapy; Bladder carcinoma; Bystander death of tumor cell; Innate immunity; Mathematical model

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CARCINOMA; BYSTANDER EFFECT; CALIBRATION; CANCER IMMUNOTHERAPY; CELL KILLING; DRUG INSTILLATION; EFFECTOR CELL; IMMUNE SYSTEM; INNATE IMMUNITY; MATHEMATICAL MODEL; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 84874530361     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.1.17884     Document Type: Article

References (41)

1. Patton SE, Hall MC, Ozen H. Bladder cancer. Curr Opin Oncol 2002; 14:265-72; DOI:10.1097/00001622-200205000-00003.
2. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353:1689-94; DOI:10.1016/S0140-6736(98)07422-4.
3. Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007; 61:299-305; DOI:10.1016/j.biopha.2007.05.004.
4. Metts MC, Metts JC, Milito SJ, Thomas CR Jr. Bladder cancer: a review of diagnosis and management. J Natl Med Assoc 2000; 92:285-94
5. Utz DC, Farrow GM. Management of carcinoma in situ of the bladder: the case for surgical management. Urol Clin North Am 1980; 7:533-41.
6. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992; 19:499-508.
7. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995; 153:1444-50; DOI:10.1016/S0022-5347(01)67427-5.
8. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56:247-56; DOI:10.1016/j.eururo.2009.04.038.
9. Meyer JP, Persad R, Gillatt DA. Use of bacille Calmette-Guerin in superficial bladder cancer. Postgrad Med J 2002; 78:449-54; DOI:10.1136/pmj.78.922.449.
10. Morales A. Intravesical therapy of bladder cancer: an immunotherapy success story. Int J Urol 1996; 3:329-33; DOI:10.1111/j.1442-2042.1996.tb00548.x.
11. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980; 124:38-40.
12. De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, De Groot ER, et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother 1992; 34:306-12; DOI:10.1007/BF01741551.
13. Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stockle M, Jocham D, et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006; 66:8250-7; DOI:10.1158/0008-5472.CAN-06-1416.
14. Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T, Kanetake H, et al. Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer. Clin Exp Immunol 1999; 115:131-5; DOI:10.1046/j.1365-2249.1999.00756.x.
15. Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 1995; 99:369-75; DOI:10.1111/j.1365-2249.1995.tb05560.x.
16. Siracusano S, Vita F, Abbate R, Ciciliato S, Borelli V, Bernabei M, et al. The role of granulocytes following intravesical BCG prophylaxis. Eur Urol 2007; 51:1589-97; DOI:10.1016/j.eururo.2006.11.045.
17. Clark RA, Klebanoff SJ. Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system. J Exp Med 1975; 141:1442-7; DOI:10.1084/jem.141.6.1442.
18. Rosevear HM, Lightfoot AJ, O'Donnell MA, Griffith TS. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev 2009; 28:345-53; DOI:10.1007/s10555-009-9195-6.
19. Simons MP, Leidal KG, Nauseef WM, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules. J Leukoc Biol 2008; 83:621-9; DOI:10.1189/jlb.0707452.
20. Griffith TS, Kucaba TA, O'Donnell MA, Burns J, Benetatos C, McKinlay MA, et al. Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist. Apoptosis 2011; 16:13-26; DOI:10.1007/s10495-010-0535-3.
21. Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, et al. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer. J Urol 2009; 181:1571-80; DOI:10.1016/j.juro.2008.11.124.
22. Seow SW, Rahmat JN, Bay BH, Lee YK, Mahendran R. Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guerin or Lactobacillus rhamnosus strain GG in the healthy murine bladder. Immunology 2008; 124:419-27; DOI:10.1111/j.1365-2567.2007.02792.x.
23. Yutkin V, Pode D, Pikarsky E, Mandelboim O. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. J Urol 2007; 178:2660-4; DOI:10.1016/j.juro.2007.07.118.
24. Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic and inflammatory cell responses of the bladder to intravesical BCG treatment
25. Saban MR, Backer JM, Backer MV, Maier J, Fowler B, Davis CA, et al. VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation. Am J Physiol Renal Physiol 2008; 295:60-72; DOI:10.1152/ajprenal.00618.2007.
26. Durek C, Richter E, Basteck A, Rusch-Gerdes S, Gerdes J, Jocham D, et al. The fate of bacillus Calmette-Guerin after intravesical instillation. J Urol 2001; 165:1765-8; DOI:10.1016/S0022-5347(05)66410-5.
27. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 1990; 85:62-7; DOI:10.1172/JCI114434.
28. Bevers RF, Kurth KH, Schamhart DH. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 2004; 91:607-12.
29. Simons MP, O'Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 2008; 26:341-5; DOI:10.1016/j.urolonc.2007.11.031.
30. Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy. Eur Urol 2009; 55:1386-95; DOI:10.1016/j.eururo.2009.01.040.
31. Chtanova T, Schaeffer M, Han SJ, van Dooren GG, Nollmann M, Herzmark P, et al. Dynamics of neutrophil migration in lymph nodes during infection. Immunity 2008; 29:487-96; DOI:10.1016/j.immuni.2008.07.012.
32. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303:1532-5; DOI:10.1126/science.1092385.
33. Cerwenka A, Lanier LL. Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev 2001; 181:158-69; DOI:10.1034/j.1600-065X.2001.1810113.x.
34. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, et al. NK cells and cancer. J Immunol 2007; 178:4011-6.
35. Smith JA. Neutrophils, host defense and inflammation: a double-edged sword. J Leukoc Biol 1994; 56:672-86.
36. Michelson S, Leith JT. Dormancy, regression and recurrence: towards a unifying theory of tumor growth control. J Theor Biol 1994; 169:327-38; DOI:10.1006/jtbi.1994.1155.
37. Bunimovich-Mendrazitsky S, Shochat E, Stone L. Mathematical model of BCG immunotherapy in superficial bladder cancer. Bull Math Biol 2007; 69:1847-70; DOI:10.1007/s11538-007-9195-z.
38. Jackson A, Alexandroff AB, Fleming D, Prescott S, Chisholm GD, James K. Bacillus-Calmette-Guerin (Bcg) Organisms Directly Alter the Growth of Bladder-Tumor Cells. Int J Oncol 1994; 5:697-703.
39. Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 2010; 184:1915-9; DOI:10.1016/j.juro.2010.06.147.
40. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001; 166:1300-4; DOI:10.1016/S0022-5347(05)65757-6.
41. Gillespie D, Petzold L. Improved leap-size selection for accelerated stochastic simulation. J Chem Phys 2003; 119:8229; DOI:10.1063/1.1613254.